Perspective - (2025) Volume 9, Issue 5
Received: 03-Oct-2025, Manuscript No. jcre-26-187224;
Editor assigned: 06-Oct-2025, Pre QC No. P-187224;
Reviewed: 20-Oct-2025, QC No. Q-187224;
Revised: 24-Oct-2025, Manuscript No. R-187224;
Published:
31-Oct-2025
, DOI: 10.37421/2795-6172.2025.9.354
Citation: Suleiman, Ibrahim. ”Antipsychotic Medications: Efficacy, Tolerability, And Choice.” J Clin Res 09 (2025):354.
Copyright: © 2025 Suleiman I. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
The management of schizophrenia has seen significant advancements with the development of a diverse range of antipsychotic medications, each offering unique profiles of efficacy and tolerability. Early comparative studies have laid the groundwork for understanding these differences, with research by Lewis et al. in 2022 comparing Aripiprazole and Risperidone, highlighting Aripiprazole's more favorable side effect profile, particularly regarding metabolic parameters and extrapyramidal symptoms [1].
Further exploration into long-term treatment options has been provided by Evans et al. in 2021, who investigated Olanzapine and Quetiapine in first-episode psychosis. Their findings indicated comparable efficacy in symptom reduction but noted significant differences in weight gain and metabolic disturbances, with Olanzapine demonstrating a higher incidence [2].
For individuals with treatment-resistant schizophrenia, Clozapine remains a critical therapeutic option. A systematic review and meta-analysis by White et al. in 2023 consistently demonstrated Clozapine's superior efficacy in reducing positive and negative symptoms and improving overall functioning, despite its associated monitoring requirements [3].
In the realm of long-acting injectables (LAIs), the effectiveness of such formulations in improving adherence and reducing relapse rates has been a focus of research. Miller et al. in 2020 conducted a real-world study comparing Paliperidone palmitate LAI with oral Risperidone, finding that the LAI was associated with significantly lower relapse rates and improved adherence [4].
The acute treatment phase of schizophrenia also benefits from optimized medication selection. Taylor et al. in 2022 conducted a double-blind randomized controlled trial comparing Lurasidone and Haloperidol for acute exacerbations, reporting similar efficacy in symptom reduction but a more favorable tolerability profile for Lurasidone, with fewer extrapyramidal side effects [5].
Ongoing research continues to refine our understanding of newer agents. Lee et al. in 2021 evaluated Brexpiprazole against Aripiprazole in patients with schizophrenia, observing significant improvements in positive and negative symptoms for both, with Brexpiprazole showing a trend towards better tolerability concerning weight gain and sedation [6].
Real-world effectiveness studies are crucial for understanding how these medications perform outside of controlled trial settings. A study by Baker et al. in 2023 compared Cariprazine and Paliperidone over one year, finding both effective in reducing symptom severity, but Cariprazine was associated with a lower incidence of hyperprolactinemia and weight gain [7].
Cognitive deficits are a significant challenge in schizophrenia, and research has begun to explore how antipsychotics impact these domains. Walker et al. in 2020 assessed the impact of Ziprasidone versus Olanzapine on cognitive function, noting that Ziprasidone demonstrated a statistically significant benefit in certain cognitive domains [8].
The role of LAIs in maintaining remission is further supported by research such as that of Brown et al. in 2022, who compared Invega Sustenna (paliperidone palmitate once-monthly injection) with oral Haloperidol, finding the LAI to be superior in preventing relapse and associated with better adherence [9].
Finally, contextualizing treatment choices within specific populations is important. Adebayo et al. in 2021 conducted a comparative study of Perphenazine versus Risperidone in Nigeria, finding both effective but with different side effect profiles, highlighting the need to consider local context and individual risk factors [10].
The comparative efficacy and tolerability of various antipsychotic medications in managing schizophrenia and related psychotic disorders continue to be a focal point of clinical research. In a notable study, Lewis et al. (2022) compared Aripiprazole and Risperidone for schizophrenia management, concluding that while both are effective, Aripiprazole exhibited a more favorable side effect profile, especially concerning metabolic parameters and extrapyramidal symptoms, suggesting its potential as a preferred long-term option for at-risk patients [1].
Addressing the critical aspect of long-term treatment in first-episode psychosis, Evans et al. (2021) conducted a randomized controlled trial comparing Olanzapine and Quetiapine. Their research revealed comparable efficacy in symptom reduction but highlighted significant differences in weight gain and metabolic disturbances, with Olanzapine associated with a higher incidence, underscoring the importance of individualized treatment selection based on metabolic risk factors [2].
For the challenging subset of patients with treatment-resistant schizophrenia, Clozapine remains a cornerstone of therapy. A comprehensive systematic review and meta-analysis by White et al. (2023) reaffirmed Clozapine's superior efficacy in alleviating positive and negative symptoms and enhancing overall functioning, despite its rigorous monitoring requirements and potential side effects, emphasizing its vital role for a substantial patient subgroup [3].
The evolution of antipsychotic delivery systems has also seen a significant focus on long-acting injectable (LAI) formulations to improve adherence and outcomes. Miller et al. (2020) provided real-world evidence by comparing Paliperidone palmitate LAI with oral Risperidone in schizophrenia management, demonstrating that the LAI formulation was linked to significantly lower relapse rates and improved adherence, leading to better clinical results and quality of life [4].
In the acute phase of schizophrenia, optimizing symptom management while minimizing adverse effects is paramount. Taylor et al. (2022) conducted a double-blind randomized controlled trial comparing Lurasidone with Haloperidol for acute exacerbations. The study found similar efficacy in reducing psychotic symptoms but noted Lurasidone's more favorable tolerability, characterized by fewer extrapyramidal side effects and less sedation, positioning it as a potentially superior option for acute treatment [5].
Recent advancements in antipsychotic development are continuously being evaluated. Lee et al. (2021) investigated the efficacy and tolerability of Brexpiprazole versus Aripiprazole in schizophrenia patients, reporting significant symptom improvements with both agents. Importantly, Brexpiprazole showed a trend towards better tolerability regarding weight gain and sedation, suggesting it as a viable alternative with a potentially improved side effect profile [6].
Real-world studies are indispensable for understanding the practical application and effectiveness of these medications in diverse patient populations. Baker et al. (2023) conducted a one-year real-world study comparing Cariprazine and Paliperidone in schizophrenia management. Both medications proved effective in reducing symptom severity, but Cariprazine was associated with a lower incidence of hyperprolactinemia and weight gain, indicating a more favorable metabolic and endocrine profile that could enhance long-term adherence and patient well-being [7].
Cognitive impairment is a pervasive symptom of schizophrenia, impacting functional outcomes. Walker et al. (2020) investigated the effect of Ziprasidone versus Olanzapine on cognitive function in patients with schizophrenia. While both drugs improved psychotic symptoms, Ziprasidone demonstrated a statistically significant benefit in specific cognitive domains, such as attention and processing speed, suggesting a potential advantage for patients with cognitive deficits [8].
The utility of LAIs in maintaining remission is further substantiated by research from Brown et al. (2022), who compared Invega Sustenna (paliperidone palmitate once-monthly injection) to oral Haloperidol in maintaining remission in schizophrenia. Their randomized controlled trial revealed Invega Sustenna's superior effectiveness in relapse prevention and better adherence rates, highlighting the benefits of LAIs for sustained symptom control [9].
Lastly, considering geographical and cultural contexts in treatment selection is vital. Adebayo et al. (2021) conducted a comparative study of Perphenazine versus Risperidone in Nigeria, finding both drugs effective in symptom reduction. However, Perphenazine was linked to a higher incidence of extrapyramidal side effects, whereas Risperidone showed a greater tendency for weight gain, indicating that treatment choices should account for local contexts and individual patient risk factors for specific side effects [10].
This collection of studies examines the efficacy and tolerability of various antipsychotic medications for schizophrenia and related disorders. Comparisons between Aripiprazole and Risperidone show Aripiprazole as having a better side effect profile, particularly metabolically. Long-term studies of Olanzapine and Quetiapine indicate similar efficacy but differing weight gain profiles, with Olanzapine causing more. Clozapine remains superior for treatment-resistant schizophrenia despite its monitoring needs. Long-acting injectables like Paliperidone palmitate demonstrate improved adherence and reduced relapse rates compared to oral formulations. Lurasidone offers a favorable tolerability profile in acute treatment, while Brexpiprazole shows potential advantages over Aripiprazole in tolerability. Cariprazine appears to have a better metabolic and endocrine profile than Paliperidone in real-world settings. Ziprasidone may offer benefits for cognitive function over Olanzapine. The choice of medication should consider individual patient factors, potential side effects, and even regional context.
None
None
Journal of Clinical Research received 11 citations as per Google Scholar report
